NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Precede Biosciences

Precede Biosciences

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.precede.bio/

Last Round

Series B

Jan 12, 2026

Total Funding Raised

$140.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Precede Biosciences is a biotechnology company that offers a liquid biopsy platform for in-depth analysis of disease-related biology through a simple blood test.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Application

Keywords

liquid biopsyprecision oncologyepigenomic analysisfunctional tumor biologycancer diagnosticsdrug resistancebiomarker discoverytranscriptional profilingcell-free DNAcfDNAclinical trial stratificationmulti-omicsai-driven diagnosticsnext-gen sequencingcompanion diagnosticsbiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Precede Biosciences Comps

Public and private peers based on sector, stage, and business model.

Precede Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Precede Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 12, 2026
DebtJan 12, 2026
Series AOct 5, 2023

Key People

Founding team and executive leadership

Rehan Verjee

Co-founder and CEO

Founding Team

Jennifer Fortune

Chief Operating Officer

Executive Team

Precede Biosciences Investors

Notable investors and investment history

Precede Biosciences investors
InvestorRounds
Binney Street CapitalSeed, Series A, Series B
Osage University PartnersSeries A, Series B
5AM VenturesSeed, Series B, Series A
Alexandria Venture InvestmentsSeries B
Mirae Asset Capital Life ScienceSeries B
Mirae Asset CapitalSeries B
Lilly Asia VenturesSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Launched Precede Bio Insight, an epigenomic liquid biopsy platform.

  • Apr 17, 2026

    Presented new data at the AACR 2026 Annual Meeting.

Precede Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Precede Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Precede Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range61
Year Founded2021
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.